Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(Anaphylaxis and Food Allergy)
4,081 results
  • Microneedles coated with peanut allergen enable desensitization of peanut sensitized mice. [Journal Article]
    J Control Release 2019Shakya AK, Ingrole RSJ, … Gill HS
  • The prevalence of peanut allergies has escalated over the last 20 years, yet there are no FDA approved treatments for peanut allergies. In this study we evaluated the potential of microneedles to deliver peanut protein extract (PE) into skin and assessed if the ensuing immune responses could desensitize mice that were sensitized to peanuts. Peanut sensitized mice were either treated through cutan…
  • Current Trends in Tolerance Induction in Cow's Milk Allergy: From Passive to Proactive Strategies. [Review]
    Front Pediatr 2019; 7:372Sackesen C, Altintas DU, … Sekerel BE
  • This review addresses the current strategies of inducing tolerance development in infant and childhood cow's milk protein allergy (CMPA). The change in prevention strategies for CMPA has been emphasized based on the lack of evidence to support the efficacy of food allergen avoidance in infancy and the concept of the dual-allergen-exposure hypothesis, which suggests that allergen exposure through …
  • Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma. [Journal Article]
    Am J Health Syst Pharm 2019; 76(21):1749-1752Choi B, McBride A, Scott AJ
  • CONCLUSIONS: Nivolumab (Opdivo, Bristol-Myers Squibb) has been Food and Drug Administration (FDA) approved for a variety of malignancies, including a recent approval for hepatocellular carcinoma (HCC). Infusion-related reactions occur in less than 1% of patients, and although such reactions are rare, recognition of infusion-related reactions induced by nivolumab is an important aspect of its usage. The PD-1 checkpoint inhibitor pembrolizumab is also FDA approved for subsequent-line therapy in treatment of HCC. Thus far, approximately 0.2% of patients experienced severe infusion-related reaction in studies using pembrolizumab. A 70-year-old male with HCC had an infusion reaction to nivolumab that presented as facial flushing, dyspnea, and back pain. The patient received prompt administration of diphenhydramine and hydrocortisone, which led to the amelioration of symptoms and allowed the patient to complete his immunotherapy treatment. For the third dose of nivolumab, the patient received premedications prior to treatment, including diphenhydramine, hydrocortisone, and famotidine. During his infusion, the patient experienced facial flushing, coughing, chest tightness, and an itchy throat. The patient again received diphenhydramine and hydrocortisone to treat infusion-related symptoms and his therapy was discontinued. Because of the nivolumab infusion-related reaction, nivolumab was discontinued, and the patient was started on pembrolizumab. The patient tolerated pembrolizumab without any subsequent infusion-related reactions. Prompt recognition and attention to immunotherapy infusion-related reactions could potentially prevent the fatal complication of anaphylaxis with immune checkpoint inhibitors. In this report, we describe the successful transition from one anti-PD-1 therapy to another for continued immunotherapy treatment without any subsequent infusion reactions.A patient with HCC was successfully treated with pembrolizumab after experiencing adverse effects with nivolumab.
  • Physicians prescribe adrenaline autoinjectors, do parents use them when needed? [Journal Article]
    Allergol Immunopathol (Madr) 2019Esenboga S, Kahveci M, … Sekerel BE
  • CONCLUSIONS: After prescription of AAI and initial training, patients and parents' concerns and fears should be taken into consideration and necessary support should be provided. At every opportunity and each clinical visit, not only should training sessions be repeated but also the patients and parents should be psychologically supported.
  • [Hypersensitivity reactions to food additives]. [Journal Article]
    Rev Alerg Mex 2019 Jul-Sep; 66(3):329-339Velázquez-Sámano G, Collado-Chagoya R, … Rosales-Guevara J
  • Food additives are ingredients that are intentionally added to food in order to modify its physical, chemical, biological, or sensorial characteristics. Food additives may act as allergens and generate IgE-mediated immune reactions, or they may act as pseudo allergens and generate non-IgE-mediated immune reactions. Such reactions can generate diverse clinical pictures or they may exacerbate disea…
  • Frequency and clinical features of pollen-food syndrome in children. [Journal Article]
    Allergol Immunopathol (Madr) 2019Guvenir H, Dibek Misirlioglu E, … Kocabas CN
  • CONCLUSIONS: PFS can be seen in children who are followed up for pollen-induced AR. The symptoms of PFS are usually mild and transient. However, comprehensive evaluation of patients is important since serious systemic reactions such as anaphylaxis can also be observed.
  • Recent developments and highlights in food allergy. [Review]
    Allergy 2019Eiwegger T, Hung L, … Upton J
  • The achievement of long lasting, safe treatments for food allergy is dependent on the understanding of the immunological basis of food allergy. Accurate diagnosis is essential for management. In recent years, data from oral food challenges have revealed that routine allergy testing is poor at predicting clinical allergy for tree nuts, almonds in particular. More advanced antigen-based tests inclu…
New Search Next